Abstract
The ‘experience curve’ shows a consistent relationship between the cost (or price) of a product, and the total production volume to that point and is observable for a wide range of products, often over surprisingly long periods of time. Evidence is presented here to indicate that medical devices also follow such curves. The benefits to be gained from wider use of such curves by manufacturers and by health technology assessment organisations, particularly for reimbursement, are presented.
Get full access to this article
View all access options for this article.
References
1.NHS National Institute for Clinical Excellence (2004 ). Guide to the methods of technology appraisal . Available from http://www.nice.org.uk/download.aspx?o=201973.
2.
Wright
T. P.
(1935 ). Factors affecting the cost of airplanes . J. Aeronaut. Sci. 3 , 275 –282 .
3.
Alchian
A.
(1963 ). Reliability of progress curves in airframe production . Econometrica 31 (4 ), 679 –693 .
4.
Henderson
B. D.
(1974 ). The experience curve — reviewed I . Concept 124 , 1 –2 .
5.
Henderson
B. D.
(1974 ). The experience curve — reviewed V . Price Stabil 149 , 1 –3 .
6.
Henderson
B. D.
(1984 ). The application and misapplication of the experience curve . J. Bus. Strat. 4 (3 ), 3 –9 .
7.
Lieberman
M. B.
(1984 ). The learning curve and pricing in the chemical processing industries . Rand J. Econ. 15 (2 ), 213 –228 .
8.
Zimmerman
M. B.
(1982 ). Learning effects and the commercialization of new energy technologies: The case of nuclear power . Bell J. Econ. 13 (2 ), 297 –310 .
9.
Gelijns
A.
Rosenberg
N.
(1994 ). The dynamics of technological change in medicine . Health Aff. 13 (3 ), 28 –46 .
10.
Bodenheimer
T.
(2005 ). High and rising health care costs. Part 2: Technologic innovation . Ann. Intern. Med. 142 (11 ), 932 –937 .
11.
Lubitz
J.
(2005 ). Health, technology and medical care spending . Health Affairs 24 , 81 –86 .
12.
Rettig
R. A.
(1994 ). Medical innovation duels cost containment . Health Affairs 13 (3 ), 7 –27 .
13.
Newhouse
J. P.
(1992 ). Medical care costs: How much welfare loss? . J. Econ. Perspect. 6 (3 ), 3 –21 .
14.
Parmenter
E. M.
(2004 ). Health care benefit crisis: Cost drivers and strategic solutions . J. Financ. Serv. Professionals 58 (4 ), 63 –78 .
15.
Neumann
P. J.
Rosen
A. B.
Weinstein
M. C.
(2005 ). Medicare and cost-effectiveness analysis . N. Engl. J. Med. 353 (14 ), 1516 –1522 .
16.
Cohen
B.
(2006 ) Drug eluting stents . www.Angioplasty.org. http://www.ptca.org/articles/des.html. Accessed 23rd August, 2006.
17.Boston Scientific Inc. (2006 ). Drug-eluting stenting , Boston Scientific Inc. Available at: http://www.bostonscientific.com/patient_ed/PEprocedureOverview.jsp?task=tskPEprocedureOverview.jsp§ionId=3&relId=1001,1016. Accessed 23rd August, 2006.
18.Cordis Corporation (2006 ). Cypher: How does it work? , Cordis Corporation . http://www.cypherusa.com/cypher-j2ee/cypherjsp/about/how_does_it_work.jsp. Accessed 23rd August, 2006.
19.
Inflationdata.com
(2006 ) Historical CPI-U data from 1913 to the present Inflationdata.com http://inflationdata.com/Inflation/Consumer_Price_Index/HistoricalCPI.aspx. Accessed 21st August, 2006.
20.Office of National Statistics (2006 ). Consumer Prices Index (CPI) , Office of National Statistics . http://www.statistics.gov.uk/STATBASE/tsdataset.asp?vlnk=7174&More=N&All=Y. Accessed 21st August, 2006.
21.
Buxton
A. E.
(2003 ). The clinical use of implantable cardioverter defibrillators: Where are we now? Where should we go? . Ann. Intern. Med. 138 (6 ), 512 –514 .
22.
Buxton
M.
Caine
N.
Chase
D.
Connelly
D.
Grace
A.
Jackson
C.
Parkes
J.
Sharples
L.
(2006 ). A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and the modelling of cost-effectiveness and cost-utility for these groups in a UK context . 10 (27 ), 1 –164 .